Publisher DOI: | 10.1186/s13023-022-02176-1 | Title: | Dual guidance structure for evaluation of patients with unclear diagnosis in centers for rare diseases (ZSE-DUO) : study protocol for a controlled multi-center cohort study | Language: | English | Authors: | Hebestreit, Helge Zeidler, Cornelia Schippers, Christopher de Zwaan, Martina Deckert, Jürgen Heuschmann, Peter Krauth, Christian Bullinger, Monika Berger, Alexandra Berneburg, Mark Brandstetter, Lilly Deibele, Anna Dieris-Hirche, Jan Graeßner, Holm Gündel, Harald Herpertz, Stephan Heuft, Gereon Lapstich, Anne-Marie Lücke, Thomas Maisch, Tim Mundlos, Christine Petermann-Meyer, Andrea Müller, Susanne Ott, Stephan Pfister, Lisa Quitmann, Julia ![]() Romanos, Marcel Rutsch, Frank Schaubert, Kristina Schubert, Katharina Schulz, Jörg Bernhard Schweiger, Susann Tüscher, Oliver Ungethüm, Kathrin Wagner, Thomas O. F. Haas, Kirsten |
metadata.local.contributorCorporate.other: | ZSE-DUO Working Group | Keywords: | Cohort study; Mental health disorders; Rare diseases; Uncleardiagnosis; Undetermined symptoms | Issue Date: | 14-Feb-2022 | Publisher: | BioMed Central | Journal or Series Name: | Orphanet journal of rare diseases | Volume: | 17 | Issue: | 1 | Abstract: | Background In individuals suffering from a rare disease the diagnostic process and the confirmation of a final diagnosis often extends over many years. Factors contributing to delayed diagnosis include health care professionals' limited knowledge of rare diseases and frequent (co-)occurrence of mental disorders that may complicate and delay the diagnostic process. The ZSE-DUO study aims to assess the benefits of a combination of a physician focusing on somatic aspects with a mental health expert working side by side as a tandem in the diagnostic process. Study design This multi-center, prospective controlled study has a two-phase cohort design. Methods Two cohorts of 682 patients each are sequentially recruited from 11 university-based German Centers for Rare Diseases (CRD): the standard care cohort (control, somatic expertise only) and the innovative care cohort (experimental, combined somatic and mental health expertise). Individuals aged 12 years and older presenting with symptoms and signs which are not explained by current diagnoses will be included. Data will be collected prior to the first visit to the CRD’s outpatient clinic (T0), at the first visit (T1) and 12 months thereafter (T2). Outcomes Primary outcome is the percentage of patients with one or more confirmed diagnoses covering the symptomatic spectrum presented. Sample size is calculated to detect a 10 percent increase from 30% in standard care to 40% in the innovative dual expert cohort. Secondary outcomes are (a) time to diagnosis/diagnoses explaining the symptomatology; (b) proportion of patients successfully referred from CRD to standard care; (c) costs of diagnosis including incremental cost effectiveness ratios; (d) predictive value of screening instruments administered at T0 to identify patients with mental disorders; (e) patients’ quality of life and evaluation of care; and f) physicians’ satisfaction with the innovative care approach. Conclusions This is the first multi-center study to investigate the effects of a mental health specialist working in tandem with a somatic expert physician in CRDs. If this innovative approach proves successful, it will be made available on a larger scale nationally and promoted internationally. In the best case, ZSE-DUO can significantly shorten the time to diagnosis for a suspected rare disease. Trial registration ClinicalTrials.gov; Identifier: NCT03563677; First posted: June 20, 2018, https://clinicaltrials.gov/ct2/show/NCT03563677. |
URI: | https://hdl.handle.net/20.500.12738/17218 | ISSN: | 1750-1172 | Review status: | This version was peer reviewed (peer review) | Institute: | Universitätsklinikum Hamburg-Eppendorf | Type: | Article | Additional note: | article number: 47 (2022) |
Appears in Collections: | Publications without full text |
Show full item record
Add Files to Item
Note about this record
Export
This item is licensed under a Creative Commons License